The provided sources do not mention the percentage of the Vascepa discount. However, they provide some relevant information about Vascepa.

Vascepa's active ingredient is icosapent ethyl, which is a prescription medication used to treat high triglyceride levels in the blood. According to DailyMed [3], Vascepa is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Amarin Corporation, the manufacturer of Vascepa, announced on November 16, 2020, that the US Food and Drug Administration (FDA) granted priority review for Vascepa's supplemental new drug application [2]. The application is for an indication expansion to include the treatment of adults with high triglyceride levels who are at increased risk of cardiovascular events, such as heart attack and stroke.

Drug Patent Watch [1] provides information on the patent status of Vascepa. According to the website, Vascepa's first patent expires on July 25, 2025, and the drug has no generic competitors.

In summary, the sources do not provide information about the percentage of the Vascepa discount. However, they offer some relevant information about the drug, including its active ingredient, indication, and patent status.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://investor.amarincorp.com/news-releases/news-release-details/us-fda-grants-priority-review-vascepar-icosapent-ethyl
[3] https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c1a2828-1583-4414-ab22-a60480e8e508